Meeting
2018 ASCO Annual Meeting
A phase 3 study comparing polatuzumab vedotin plus R-CHP versus R-CHOP in patients with DLBCL (POLARIX).
Authors
Herve Tilly
Centre Henri Becquerel, University of Rouen, Rouen, France
Herve Tilly , Christopher Flowers , Jonathan W. Friedberg , Charles Herbaux , Franck Morschhauser , Laurie Helen Sehn , Jeff Porter Sharman , Marek Trněný , Lijia Wang , Calvin Lee , Gilles A. Salles
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Track
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Sub Track
Non-Hodgkin Lymphoma
Clinical Trial Registration Number
NCT03274492
Citation
J Clin Oncol 36, 2018 (suppl; abstr TPS7589)
DOI
10.1200/JCO.2018.36.15_suppl.TPS7589
Abstract #
TPS7589
Poster Bd #
222a
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
POLARIX: A phase 3 study of polatuzumab vedotin (pola) plus R-CHP versus R-CHOP in patients (pts) with untreated DLBCL.
First Author: Herve Tilly
Poster
2023 ASCO Annual Meeting
Subgroup analysis of elderly patients (pts) with diffuse large B-cell lymphoma (DLBCL) in the phase 3 POLARIX study.
First Author: Bei Hu
Poster
2022 ASCO Annual Meeting
frontMIND: A phase III, randomized, double-blind study of tafasitamab + lenalidomide + R-CHOP versus R-CHOP alone for newly diagnosed high-intermediate and high-risk diffuse large B-cell lymphoma.
First Author: Umberto Vitolo
